ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
110.82
-0.38 (-0.34%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close111.20
Open111.51
Bid108.85 x 800
Ask109.75 x 800
Day's Range108.90 - 112.50
52 Week Range58.03 - 133.74
Volume576,495
Avg. Volume509,083
Market Cap3.286B
Beta (3Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)-12.17
Earnings DateFeb 12, 2019 - Feb 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est147.40
Trade prices are not sourced from all markets
  • Health care going negative after starting quarter strong
    CNBC Videos2 months ago

    Health care going negative after starting quarter strong

    CNBC's Bertha Coombs evaluates the outlook for the health-care industry next year.

  • Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
    Motley Fool9 hours ago

    Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals

    Which of these NASH stocks is the better pick right now?

  • Benzinga4 days ago

    Analyst: Intercept's NASH Drug Could Launch Sans Competition After Gilead Trial Failure

    With Gilead Sciences, Inc. (NASDAQ: GILD )'s NASH setback, Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT )'s Ocaliva, which is being evaluated in a late-stage study for NASH with fibrosis, is taking the ...

  • Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails
    Zacks5 days ago

    Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails

    Gilead (GILD) suffers a setback as its phase III study on pipeline candidate, selonsertib, in patients with compensated cirrhosis (F4) due to NASH fails to meet goal.

  • Is Intercept Pharmaceuticals a Buy?
    Motley Fool8 days ago

    Is Intercept Pharmaceuticals a Buy?

    Can the momentum continue for this hot biotech stock?

  • Markit10 days ago

    See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.

    Intercept Pharmaceuticals Inc NASDAQ/NGS:ICPTView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for ICPT with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ICPT totaled $4.26 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks12 days ago

    Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • ACCESSWIRE18 days ago

    Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Moderna

    NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged ...

  • Benzinga18 days ago

    JMP Upgrades Intercept Pharma Ahead Of NASH Trial Data

    Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) recently announced Jan. 7 that it expects to release top-line data from the interim analysis of the Phase 3 study dubbed "REGENERATE" during the ...

  • The Biggest Biotech Binary Event in 2019 Is Just Around the Corner
    Motley Fool19 days ago

    The Biggest Biotech Binary Event in 2019 Is Just Around the Corner

    Investors, mark your calendars.

  • NASH Space in Focus in 2019 as Firms Look to Diversify
    Zackslast month

    NASH Space in Focus in 2019 as Firms Look to Diversify

    NASH is a highly lucrative market with blockbuster potential. Hence, we take a look at some of the companies in this space.

  • Are Options Traders Betting on a Big Move in Intercept Pharmaceuticals (ICPT) Stock?
    Zackslast month

    Are Options Traders Betting on a Big Move in Intercept Pharmaceuticals (ICPT) Stock?

    Investors need to pay close attention to Intercept Pharmaceuticals (ICPT) stock based on the movements in the options market lately.

  • Gilead (GILD) Collaborates With Yuhan for NASH Candidates
    Zackslast month

    Gilead (GILD) Collaborates With Yuhan for NASH Candidates

    Gilead (GILD) collaborates with Korean company Yuhan for the development of NASH treatments.

  • GlobeNewswirelast month

    Intercept Announces NASH and PBC Program Updates

    Top-line data from the interim analysis of the Phase 3 REGENERATE trial of obeticholic acid (OCA) in nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis.

  • GlobeNewswire2 months ago

    Intercept to Present at Upcoming Investor Conference

    NEW YORK, Jan. 02, 2019 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.

  • CNBC2 months ago

    The $35 billion race to cure a liver disease that affects 30 million Americans

    The race is on in the pharmaceutical industry to develop drugs to treat a form of fatty liver disease called nonalcoholic steatohepatitis, also known as NASH. The U.S. is spending $5 billion annually in health-care costs related to the disease, which include chemotherapy, transplants, tests and hospitalizations, reports the Center for Disease Analysis. The National Institutes of Health estimates as many as 12 percent of U.S. adults have this disease, or 30 million people.

  • Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018
    Zacks2 months ago

    Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018

    Intercept (ICPT) outperforms the broader market in 2018 as lead drug Ocaliva recovers, following the company's efforts to increase awareness about the updated label.

  • My Top Portfolio Holdings for 2019
    Motley Fool2 months ago

    My Top Portfolio Holdings for 2019

    Two industries are dominating my portfolio as we enter the new year.

  • Better Buy: Intercept Pharmaceuticals vs. Viking Therapeutics
    Motley Fool2 months ago

    Better Buy: Intercept Pharmaceuticals vs. Viking Therapeutics

    Both of these NASH stocks have what it takes to overcome a bear market, but which is the better pick now?

  • Is Intercept Pharmaceuticals, Inc.’s (NASDAQ:ICPT) CEO Pay Justified?
    Simply Wall St.2 months ago

    Is Intercept Pharmaceuticals, Inc.’s (NASDAQ:ICPT) CEO Pay Justified?

    Mark Pruzanski has been the CEO of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) since 2002. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then Read More...

  • Hedge Funds Are Betting On Intercept Pharmaceuticals Inc (ICPT)
    Insider Monkey2 months ago

    Hedge Funds Are Betting On Intercept Pharmaceuticals Inc (ICPT)

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The one and a half month time period since the end of the […]

  • InvestorPlace2 months ago

    The 10 Best Stocks to Buy to Finish Out 2018

    At a time when other social networking sites like Facebook (NASDAQ:FB) are struggling to figure out their place in the foreseeable future, Twitter (NYSE:TWTR) is enjoying the fact that it has just recently figured out what it is and how to sell itself. The pros are calling for sales growth of nearly 14% next year, though, which should drive the bottom line up to 89 cents per share of TWTR stock. The trading crowd hasn’t exactly priced Twitter shares like the growth machine it is.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Ultragenyx Pharmaceutical

    NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...